CD70 and T-cell non-Hodgkin lymphoma: In the Phase I COBAL-LYM dose escalation study of allogeneic CD70-CAR T-cells (CTX 130) for R/R mature T-cell lymphomas, among four patients with PTCL treated at the dose level of 3–4 the ORR was 75% [98].